C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Pipeline

DelveInsight’s, “C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) - Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC): Understanding

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC): Overview

C-Met mutated non-small cell lung cancer (NSCLC) is a distinct molecular subtype of lung cancer characterized by aberrations in the MET proto-oncogene, which encodes a receptor tyrosine kinase involved in cell growth, survival, and metastasis through the hepatocyte growth factor (HGF)/MET signaling pathway. These mutations, particularly MET exon 14 skipping events, lead to impaired degradation of the c-Met receptor and result in prolonged oncogenic signaling, driving tumor progression. Found in approximately 2–4% of NSCLC cases, C-Met mutations are more prevalent in adenocarcinoma histology and are frequently observed in elderly patients, females, and Asian populations. In addition to exon 14 skipping, MET amplification and protein overexpression contribute to ligand-independent receptor activation and may occur independently or as resistance mechanisms to other targeted therapies such as EGFR or ALK inhibitors. C-Met mutated NSCLC demonstrates variable prognostic outcomes but shows robust responsiveness to MET tyrosine kinase inhibitors, particularly in previously treated advanced-stage patients.

The diagnosis of C-Met mutated non-small cell lung cancer (NSCLC) relies on a spectrum of molecular techniques tailored to detect MET exon 14 skipping mutations, amplifications, and protein overexpression with varying sensitivity and specificity. Next-generation sequencing (NGS), particularly RNA-based assays, remains the gold standard due to its superior ability to capture the diverse splice-site alterations associated with METex14 skipping. Real-time PCR (RT-PCR) offers a cost-effective and sensitive alternative but is limited by tissue quality. Immunohistochemistry (IHC) enables assessment of MET protein overexpression, though it lacks reliability in identifying underlying genomic alterations. Liquid biopsy using circulating tumor DNA provides a non-invasive diagnostic option, with increasing concordance to tissue-based NGS in advanced or inoperable cases.

Treatment of C-Met mutated non-small cell lung cancer (NSCLC), particularly in the context of MET exon 14 skipping mutations, has been revolutionized by selective MET tyrosine kinase inhibitors (TKIs) such as capmatinib, tepotinib, and savolitinib, which have demonstrated robust clinical efficacy with response rates up to 70% in first-line settings. These agents offer durable disease control and survival benefits. Emerging strategies, including dual inhibition with EGFR or immune checkpoint inhibitors, are being explored to overcome resistance mechanisms linked to MET dysregulation. Overall, MET-targeted therapies are well tolerated, with manageable side effects predominantly consisting of edema, hepatic enzyme elevations, and mild gastrointestinal symptoms.

"C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) pipeline landscape is provided which includes the disease overview and C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) treatment guidelines. The assessment part of the report embraces, in depth C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) R&D. The therapies under development are focused on novel approaches to treat/improve C-Met Mutated Non-Small Cell Lung Cancer (NSCLC).

 

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Emerging Drugs Chapters

This segment of the C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Emerging Drugs

ABN 401: Abion Bio

ABN401 is an innovative tyrosine kinase inhibitor specifically designed to target c-Met mutant cancers. It represents a precision oncology medicine targeting c-MET, a key player implicated in the development of various solid tumors. ABN401 functions as a targeted anti-cancer agent by precisely obstructing signal transduction. By binding to the ATP-binding sites and inhibiting phosphorylation of downstream signaling, ABN401 effectively disrupts the aberrant signaling cascade. Importantly, it has also demonstrated efficacy in MET mutant cancer cells that are not reliant on HGF for activation. In Phase I clinical trials, ABN401 has demonstrated exceptional safety profiles. During a dose-escalation study, no grade 3 or higher adverse events were reported, indicating a favorable safety profile. Promising efficacy outcomes were observed, with two partial response noted during the Phase I trial. Currently, the drug is being evaluated under Phase II stage of its clinical trial.

 Further product details are provided in the report……..

 

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC): Therapeutic Assessment

This segment of the report provides insights about the different C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) drugs segregated based on following parameters that define the scope of the report, such as:

 

Major  Players in C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)

• There are approx. 4+ key companies which are developing the therapies for C-Met Mutated Non-Small Cell Lung Cancer (NSCLC). The companies which have their C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) drug candidates in the most advanced stage, i.e. Phase II include, Abion Bio.

 

Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC): Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) drugs.

 

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Report Insights

• C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) drugs?
• How many C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) and their status?
• What are the key designations that have been granted to the emerging drugs?

Stay Updated with us for Recent Articles

• The Next Chapter in NSCLC Treatment Space: Recent Discoveries and Innovations
• Novel mutation-targeting therapies in the horizon to relieve the global healthcare burden NSCLC poses
• Non-Small Cell Lung Cancer Market: Treatments and Market Forecast
• Evaluating Key Advancements and Emerging Therapies in EGFR-Non Small Cell Lung Cancer Treatment Market
• Novel Insights Into The Non-Small Cell Lung Cancer Market
• Evolving Landscape for Rare Biomarkers in Non-Small Cell Lung Cancer
• Latest DelveInsight Blogs

Related Infographics of the Report

• BRAF Non-Small Cell Lung Cancer (BRAF+ NSCLC) Market
• ALK Non-Small Cell Lung Cancer (ALK+ NSCLC) Market
• c-MET Non-Small Cell Lung Cancer (c-MET+ NSCLC) Market
• EGFR Non-Small Cell Lung Cancer (EGFR+ NSCLC) Market
• PD-L1Non-Small Cell Lung Cancer (PD-L1+ NSCLC) Market

Stay Updated with us for Recent Articles @ Latest DelveInsight Blogs